Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The drug demonstrated meaningful activity across all FRα expression levels with a favorable tolerability profile, particularly at the lower dose, supporting continued clinical development.